|Day Low/High||269.79 / 273.83|
|52 Wk Low/High||223.25 / 363.92|
The RMPIA easily outpaced the main indexes for 2020, but slipped 1.7% last month.
As we enter the new year, there's little time to reflect on RMPIA's strong performance. Now, it's all eyes on the 12 months ahead of us.
The RMPIA also tops other indexes for year, shooting ahead 29%.
These names are displaying both technical and quantitative deterioration.
The average declined in October, but it was less than that hit took by the major indexes.
There is a presidential debate on Thursday. The market is being forced to adjust for renewed potential uncertainty.
This is the type of chart that will grab the attention of momentum traders.
RedHill Biopharma has adopted 'Veeva Vault CDMS', Veeva's modern cloud platform.
Covid-19 has had a big impact on this sector, but these names have strong catalysts going into the next quarter.
The Real Money Post Industrial Average is up nearly 11% so far this quarter, beating all major indices, but valuations are looking stretched.
The markets are really in the hands of Washington right now, and Washington is in the hands of the virus.
The RMPIA rebounded more than 22% in the June quarter to finish up 7.8% at the 2020 half mark.
Let's look at the chart and see how I'd trade AA.
Let's take a close look at BIIB and arrive at a strategy for the shares.
These pharmaceutical favorites continue to make progress on a number of fronts including a Covid-19 vaccine.
Trading volumes dropping on major indexes, U.K. teams begin human trials on a Covid-19 vaccine, and the U.S. Senate wants another stimulus package addition.
A bear market, if it gets us all to slow down, may be necessary to slow the coronavirus' spread -- but this doesn't mean I'm giving up. To the contrary.
Let's check out the charts of SGMO and come up with a trading strategy.
Amid a flood of corporate warnings over the coronavirus, all the major stock market indexes finished last month down 6.4% to 10.1%.
It's no secret that the Fed would like to get out of the short-term repo business.
The Medical Technology Stock Letter's top pick rose 357% in 2019.